Compare Quest Diagnostics Inc (DGX) vs Enbridge Inc (ENB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Enbridge Inc — how do they compare? Quest Diagnostics Inc trades at $236.83 (market cap $26.21B), while Enbridge Inc trades at $51.82 (market cap $112.62B). The key difference: Enbridge Inc is far larger — about 4.3× Quest Diagnostics Inc's market cap, and Enbridge Inc pays the higher dividend (5.34%). Which is the better fit depends on your goals.
| DGX | ENB | |
|---|---|---|
Market Cap | $26.21B | $112.62B |
Sector | Health | Energy |
52-Week High | $238.50 | $58.04 |
52-Week Low | $173.49 | $45.23 |
Enterprise Value | $31.97B | $196.53B |
Dividend Yield | 1.45% | 5.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
Enbridge (ENB) trades at $51.39, up 0.21% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $65.2B revenue, 11.5% net margin, and consistent dividend growth spanning 31 years. Recent Q2 2026 results exceeded expectations with $0.46 EPS versus $0.43 estimate, supported by robust pipeline and utility performance. Analyst sentiment is balanced with 48% buy ratings while technical indicators show oversold conditions with RSI at 14.8.
ENB presents a compelling income opportunity with 5.3% dividend yield and $41B growth pipeline, though faces regulatory risks from Line 5 litigation and Wisconsin tribal land dispute. The stock's current valuation at 27.8x P/E appears reasonable given stable cash flows, but investors should monitor debt levels approaching 49% of assets and potential project delays affecting growth execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →
